Related Experiment Video

Updated: Aug 26, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

3.4K

SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal

Tripti Rastogi1, Nicolas Girerd1

  • 1Centre d'Investigation Clinique Pierre Drouin -INSERM - CHRU de Nancy, Institut lorrain du cœur et des vaisseaux Louis Mathieu, Nancy, France.

Heart Failure Clinics
|October 10, 2022
PubMed

Insights

Sodium-glucose transport inhibitors (SGLT2i) offer significant cardio-renal benefits for heart failure patients. These drugs improve outcomes in heart failure with reduced ejection fraction (HFrEF) and aid in midterm management.

Area of Science:

  • Cardiology
  • Nephrology
  • Pharmacology

Background:

  • Sodium-glucose transport inhibitors (SGLT2i) demonstrate efficacy in preventing heart failure (HF) across diverse patient groups.
  • Emerging data highlight SGLT2i's substantial benefits for cardiovascular and renal outcomes in patients with heart failure with reduced ejection fraction (HFrEF).

Purpose of the Study:

  • To review the combined cardiovascular and renal benefits of SGLT2i in patients diagnosed with HFrEF.
  • To explore the role of renoprotection in the midterm management of HFrEF.
  • To discuss potential strategies for integrating SGLT2i into standard HFrEF care.

Main Methods:

  • Literature review of recent clinical evidence and studies.
  • Analysis of pharmacological mechanisms underlying SGLT2i action.
  • Synthesis of data on cardiovascular and renal outcomes.

Main Results:

  • SGLT2i significantly improve cardiovascular and renal outcomes in HFrEF.
  • Renoprotective effects contribute to midterm management strategies for HFrEF.
  • Evidence supports the integration of SGLT2i into routine HFrEF care.

Conclusions:

  • SGLT2i provide significant combined cardio-renal benefits for patients with HFrEF.
  • Renoprotection is a key factor in the midterm management of HFrEF with SGLT2i.
  • Implementation strategies are crucial for optimizing SGLT2i use in HFrEF.

Keywords:
Cardiovascular outcomesHFrEFRenal outcomesSGLT2i

More Related Videos

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF03:42

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: March 29, 2024

1.6K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.0K

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
488
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
19
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
457
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
25
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
784
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
418